Exclusive Interview: Dr. William A. Carter, CEO. Hemispherx Biopharma, Inc. (AMEX:HEB) Print E-mail
By M.E.Garza   
Friday, 12 June 2009 20:48

Dr.William A. Carter, the CEO of Hemispherx Biopharma shares his thoughts on the FDA delay, the flu pandemic and 301 Moved Permanently the future of his company. Late in the interview he also answers questions submitted to us by our readers. Certainly, the interview is filled with candid revelations and interesting nuggets of new information.

Warning: Due To Heavy Traffic And Length, The Screen May Not Load For A Few Seconds. Please Be Patient.
We also have an alternate feed available if you find that this feed is slow to load.

TRT: Approximately 45 Minutes

BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and
investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus


BioMedReports Doctors Look to Combination Drug to Treat Osteoarthritis Pain and Hypertension: Approximately half, or an est... https://t.co/yNNhvVvE4a
BioMedReports Researchers Encouraged by Continued Signs of Tolerability and Disease Modification in Gene Therapy Trial for ... https://t.co/QgHolG88m4
BioMedReports Abeona Provides Update from ABO-102 Phase 1/2 Clinical Trial at Orphan Drugs & Rare Disease Conference: https://t.co/Ovfo8yVtTn $ABEO